TABLE 1.
Characteristics of included studies
| Author | Year | Design | Country | Population | PD diagnosis criteria | COVID‐19 diagnosis criteria | Case/exposed definition | Control/non‐exposed definition | Matching factors |
|---|---|---|---|---|---|---|---|---|---|
| Del Prete | 2020 | Case‐control study | Italy | PD patients | MDS‐PD | Laboratory a | PD patients with COVID‐19 | PD patients without COVID‐19 | Age and disease duration |
| Fasano | 2020 | Case‐control study | Italy | PD patients | MDS‐PD |
Confirmed: molecular test Probable: COVID‐19‐related symptoms |
PD patient with confirmed/probable COVID‐19 | PD patients without COVID‐19 | NR |
| Brown | 2020 | Cross‐sectional study | All continents b | PD and non‐PD patients | NR | Self‐report | Patients with COVID‐19 | Patients without COVID‐19 | DA |
| Santos‐García | 2020 | Cross‐sectional study | Spain | PD patients | NR | Laboratory a | PD patients with COVID‐19 | PD patients without COVID‐19 | DA |
| Cilia | 2020 | Case‐control study | Italy | PD patients | NR | Laboratory a | PD patients with COVID‐19 | PD patients without COVID‐19 | Sex, age, and disease duration |
| Sainz‐Amo | 2020 | Case‐control study | Spain | PD patients | MDS‐PD | Laboratory a | PD patients with COVID‐20 | PD patients without COVID‐20 | NR |
Abbreviations: DA, does not apply; MDS‐PD, Movement Disorder Society Clinical Diagnostic Criteria for PD; NR, not reported; PD, Parkinson disease.
a
Authors did not specific a method.
b
About 80% of responses were from the United States.